PTGX Valuation

Protagonist Therapeutics Inc

Add to Watchlist

Advanced Chart

78.620

+0.77(0.989%)1D

PTGX Relative Valuation

PTGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PTGX is overvalued; if below, it's undervalued.

Historical Valuation

Protagonist Therapeutics Inc (PTGX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 78.62 is considered Overvalued compared with the five-year average of -24.89. The fair price of Protagonist Therapeutics Inc (PTGX) is between 29.02 to 73.78 according to relative valuation methord. Compared to the current price of 78.62 USD , Protagonist Therapeutics Inc is Overvalued By 6.56%.

Relative Value

Fair Zone

29.02-73.78

Current Price：78.62

6.56%

Overvalued

-94.13

Trailing

Forward

-97.57

EV/EBITDA

Protagonist Therapeutics Inc. (PTGX) has a current EV/EBITDA of -97.57. The 5-year average EV/EBITDA is 0.18. The thresholds are as follows: Strongly Undervalued below -90.15, Undervalued between -90.15 and -44.98, Fairly Valued between 45.35 and -44.98, Overvalued between 45.35 and 90.51, and Strongly Overvalued above 90.51. The current Forward EV/EBITDA of -97.57 falls within the Strongly Undervalued range.

-65.80

EV/EBIT

Protagonist Therapeutics Inc. (PTGX) has a current EV/EBIT of -65.80. The 5-year average EV/EBIT is 3.69. The thresholds are as follows: Strongly Undervalued below -127.37, Undervalued between -127.37 and -61.84, Fairly Valued between 69.22 and -61.84, Overvalued between 69.22 and 134.75, and Strongly Overvalued above 134.75. The current Forward EV/EBIT of -65.80 falls within the Undervalued range.

78.62

Protagonist Therapeutics Inc. (PTGX) has a current PS of 78.62. The 5-year average PS is 41.49. The thresholds are as follows: Strongly Undervalued below -14.48, Undervalued between -14.48 and 13.50, Fairly Valued between 69.47 and 13.50, Overvalued between 69.47 and 97.46, and Strongly Overvalued above 97.46. The current Forward PS of 78.62 falls within the Overvalued range.

27.32

P/OCF

Protagonist Therapeutics Inc. (PTGX) has a current P/OCF of 27.32. The 5-year average P/OCF is 22.43. The thresholds are as follows: Strongly Undervalued below -290.10, Undervalued between -290.10 and -133.84, Fairly Valued between 178.69 and -133.84, Overvalued between 178.69 and 334.95, and Strongly Overvalued above 334.95. The current Forward P/OCF of 27.32 falls within the Historic Trend Line -Fairly Valued range.

310.54

P/FCF

Protagonist Therapeutics Inc. (PTGX) has a current P/FCF of 310.54. The 5-year average P/FCF is 33.57. The thresholds are as follows: Strongly Undervalued below -258.56, Undervalued between -258.56 and -112.50, Fairly Valued between 179.64 and -112.50, Overvalued between 179.64 and 325.71, and Strongly Overvalued above 325.71. The current Forward P/FCF of 310.54 falls within the Overvalued range.

Protagonist Therapeutics Inc (PTGX) has a current Price-to-Book (P/B) ratio of 7.31. Compared to its 3-year average P/B ratio of 4.26 , the current P/B ratio is approximately 71.52% higher. Relative to its 5-year average P/B ratio of 4.14, the current P/B ratio is about 76.56% higher. Protagonist Therapeutics Inc (PTGX) has a Forward Free Cash Flow (FCF) yield of approximately 0.76%. Compared to its 3-year average FCF yield of -2.48%, the current FCF yield is approximately -130.53% lower. Relative to its 5-year average FCF yield of -6.27% , the current FCF yield is about -112.11% lower.

7.31

P/B

Median3y

4.26

Median5y

4.14

0.76

FCF Yield

Median3y

-2.48

Median5y

-6.27

Competitors Valuation Multiple

The average P/S ratio for PTGX's competitors is 79.22, providing a benchmark for relative valuation. Protagonist Therapeutics Inc Corp (PTGX) exhibits a P/S ratio of 78.62, which is -0.76% above the industry average. Given its robust revenue growth of 33.09%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PTGX.O

Protagonist Therapeutics Inc

Akero Therapeutics Inc

54.20

4.34B

PRAX.O

Praxis Precision Medicines Inc

Performance Decomposition

Market capitalization of PTGX increased by 79.50% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 60.67 to 97.73.

The secondary factor is the Revenue Growth, contributed 33.09%to the performance.

Overall, the performance of PTGX in the past 1 year is driven by P/E Change. Which is more unsustainable.

33.09%

4.17M → 5.55M

Revenue Growth

-14.67%

-734.73 → -626.96

Margin Expansion

61.08%

60.67 → 97.73

P/E Change

79.50%